.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Management of high-grade gliomas (HGG) remains one of the most significant challenges in modern oncology. Standard care involving surgery, radiation, and temozolomide often leads to severe, persistent lymphopenia. This reduction in immune cells directly correlates with poorer survival outcomes. Consequently, researchers are investigating novel therapies like NT-I7 for gliomas to restore immune function and improve patient prognosis.
NT-I7 (efineptakin alfa) is a long-acting recombinant human interleukin-7 (IL-7). This cytokine is vital for the development, survival, and homeostasis of lymphocytes. In recent clinical trials, NT-I7 demonstrated the ability to significantly increase absolute lymphocyte counts (ALC) in patients. Therefore, it serves as a critical potential adjunct to standard treatments that typically deplete these cells.
A Phase I clinical trial recently evaluated the safety and efficacy of NT-I7 in newly diagnosed HGG patients. The study determined that NT-I7 is well-tolerated, with a maximum tolerated dose (MTD) of 720 µg/kg. Furthermore, the administration of this therapy resulted in a sustained increase in lymphocyte counts for over 12 weeks. Specifically, it induced a selective expansion of CD8+ T cell clonotypes, which are essential for anti-tumor immunity.
Moreover, the study observed early elevations in CD4+ T cells and NK cells. These changes coincided with increased levels of TNF and CXCL9 cytokines, indicating active immune engagement. Interestingly, patients with MGMT promoter-unmethylated glioblastoma—a subgroup with typically poor prognosis—showed promising clinical responses. This finding suggests that NT-I7 might be particularly beneficial when combined with other immune-based therapies.
The ability of NT-I7 to maintain immune cell populations during aggressive chemoradiotherapy is revolutionary. Because lymphopenia often limits the effectiveness of immunotherapy, reversing this state is a high priority. Currently, researchers are exploring combinations of NT-I7 with checkpoint inhibitors like pembrolizumab. Additionally, further Phase II studies will clarify its impact on overall survival and progression-free survival.
NT-I7 acts as a long-acting IL-7 analog that promotes the proliferation and survival of T cells. It specifically increases absolute lymphocyte counts and expands CD8+ T cell clones to enhance the body\'s immune response against the tumor.
The therapy was generally well-tolerated. Common adverse events included injection site reactions, flu-like symptoms, and fatigue. Dose-limiting toxicities were only noted at higher doses, leading to an MTD of 720 µg/kg.
In clinical evaluations, a single administration of NT-I7 significantly increased absolute lymphocyte counts for a duration exceeding 12 weeks.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
NT-I7 (efineptakin alfa) increases absolute lymphocyte counts and expands CD8+ T cells in high-grade glioma patients, offering a new way to combat lymphopen...
6 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
